← Back to Clinical Trials
Recruiting NCT07063602

NCT07063602 Sensory Anesthesia Achieved Through Different Paravertebral Block Approaches for Post-Op Pain Management After VATS Lung Resection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07063602
Status Recruiting
Phase
Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Condition Thoracic Surgery
Study Type OBSERVATIONAL
Enrollment 90 participants
Start Date 2025-09-10
Primary Completion 2026-09-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Evaluation of the hypoesthesia of the thorax

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 90 participants in total. It began in 2025-09-10 with a primary completion date of 2026-09-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Video-assisted thoracoscopic lung resection (VATS) is a minimally invasive surgical approach frequently used in the treatment of lung cancers. The most commonly used analgesic technique for this surgery is the paravertebral block with a single peroperative injection of local anesthetic. However, a recent study conducted at our institution revealed that this approach provided less relief than expected in some patients. In light of these results, it becomes crucial to distinguish between technical failures (absence of sensitive anesthesia) and the intrinsic limits of the chosen regional analgesia technique (pain originating from an unanesthetized area or pain despite the presence of sensitive anesthesia) in order to better relieve patients. This study aims to objectively assess the areas of anesthesia obtained through three methods of paravertebral block to evaluate their respective performance and optimize post-VATS analgesic management.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18 years and older * American Society of Anesthesiologists (ASA) score 1-3 Exclusion Criteria: * Contraindication to the paravertebral block (coagulopathy, use of anticoagulants or antiplatelet agents other than aspirin that have not been stopped according to hospital guidelines, thoracoscopic visualization of the paravertebral space expected to be difficult or impossible, anterior spinal surgery with potential discontinuity of the paravertebral space) * Epidural analgesia preferred (high risk of thoracotomy, marginal lung function) * Surgical criteria: conversion to thoracotomy necessary and thoracic epidural or other form of regional analgesia implemented post-operatively * Known allergy to local anesthetics * Language barrier, psychiatric, physical or mental condition making pain assessment impossible despite prior education * Pregnancy * Patient refusal to participate

Contact & Investigator

Central Contact

Alex Moore, MD

✉ alex.moore@umontreal.ca

📞 514-890-8000

Principal Investigator

Alex Moore, MD

PRINCIPAL INVESTIGATOR

Centre hospitalier de l'Université de Montréal (CHUM)

Frequently Asked Questions

Who can join the NCT07063602 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thoracic Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07063602 currently recruiting?

Yes, NCT07063602 is actively recruiting participants. Contact the research team at alex.moore@umontreal.ca for enrollment information.

Where is the NCT07063602 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT07063602 clinical trial?

NCT07063602 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The principal investigator is Alex Moore, MD at Centre hospitalier de l'Université de Montréal (CHUM). The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology